<DOC>
	<DOCNO>NCT01047579</DOCNO>
	<brief_summary>This study design evaluate caregiver preference Exelon® patch ( target patch size 10 cm² ) treatment patient Alzheimer 's disease ( MMSE 10-26 ) cholinesterase inhibitor treatment experience adverse event/s community setting .</brief_summary>
	<brief_title>A 12 Week , Multicenter , Open Label Evaluation Caregiver Preference , Safety Tolerability Exelon® Patch ( Rivastigmine Transdermal ) Patients With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Probable Alzheimer 's disease accord NINCDSADRDA DSMIV criterion . MMSE score &gt; 10 &lt; 26 . Patients ChE inhibitor treatment experienced adverse event . Residing someone community throughout study , live alone , contact responsible caregiver every day , primary caregiver willing accept responsibility supervise treatment condition patient . Involved clinical trial treat experimental drug within previous 4 week . Current diagnosis active skin lesion would prevent accurate assessment adhesion potential skin irritation patch . History allergy topical product contain constitution patch . Patients evidence severe unstable physical illness , i.e. , acute severe asthmatic condition , severe unstable cardiovascular disorder , etc . Patients bradycardia ( bpm le 50 ) sick sinus syndrome conduction defect ( sinoatrial block , second degree AV block ) . Patients body weight less 40 kg . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Rivastigmine transdermal</keyword>
	<keyword>caregiver preference</keyword>
</DOC>